Tag Archives: U.S.

U.S. Hospitals Will Lose $323 Billion in 2020 – Before Accounting for Growing COVID Cases

U.S. health systems are projected to lose $ 323 billion in 2020 due to declining inpatient and outpatient volumes caused by the COVID-19 pandemic’s impact on the “normal” hospital business. Hospitals racked up over $ 200 bn in losses between March and June 2020. according to the American Hospital Association’s report, Hospitals and Health Systems… Read More »

Pandemic threatens to veer out of control in U.S.

This is part of our Coronavirus Update series in which Harvard specialists in epidemiology, infectious disease, economics, politics, and other disciplines offer insights into what the latest developments in the COVID-19 outbreak may bring. Harvard public health experts said the nation’s COVID-19 epidemic is getting “quite out of hand” and that, with cases rising rapidly… Read More »

There Are 10 Million Coronavirus Cases Worldwide. The U.S. Accounts For 25% Of Them.

TOPLINE The coronavirus pandemic hit a grim milestone Sunday morning, reaching 10 million confirmed cases worldwide, according to the Johns Hopkins University tracker, with the U.S. accounting for 25% of those cases—and no slowdown of infections in sight. A man wearing a mask walks past a banner reminding people of social distancing guidelines on Santa… Read More »

From fighting Ebola to trying to wipe out polio, U.S. pullout from WHO will have tangible impact: experts

Ebola is a truly horrible disease, but the 2018-19 outbreak of the virus in the Democratic Republic of Congo was particularly chaotic, as health workers tried to save lives amid an ongoing civil war. There could have been even more disarray, says Dr. Srinivas Murthy, had the World Health Organization not overseen the various medical… Read More »

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–May 15, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst ® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are… Read More »